دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events
Felice Gragnano, MD, PH D, a,b Davide Cao, MD,c,d Leah Pirondini,e Anna Franzone, MD, P HD, f Hyo-Soo Kim, MD, P HD, g Moritz von Scheidt, MD, h Alf-?ge R. Pettersen, MD, PHD, i,j Qiang Zhao, MD, PHD, k Mark Woodward, PHD, l,m Mauro Chiarito, MD, d,n Eugene P. McFadden, MD, PHD, o,p Kyung Woo Park, MD, PH D, g Adnan Kastrati, MD,h Ingebj?rg Seljeflot, MD, P HD, j,q Yunpeng Zhu, MD,k Stephan Windecker, MD,r Jeehoon Kang, MD,g Heribert Schunkert, MD,h Harald Arnesen, MD, PH D, j,q Deepak L. Bhatt, MD, s Philippe Gabriel Steg, MD,t Paolo Calabr?, MD, PH D, a,b Stuart Pocock, P HD, e Roxana Mehran, MD,u Marco Valgimigli, MD, PH D, r,v on behalf of the PANTHER Collaboration
doi : 10.1016/j.jacc.2023.04.051
Volume 82, Issue 2, 11 July 2023, Pages 89-105
Aspirin is the only antiplatelet agent with a Class I recommendation for long-term prevention of cardiovascular events in patients with coronary artery disease (CAD). There is inconsistent evidence on how it compares with alternative antiplatelet agents.
The Optimal Antiplatelet Agent for Secondary Prevention of Coronary Artery Disease: Ring Out the Old?∗
Dharam J. Kumbhani, MD, SM, James A. de Lemos, MD
doi : 10.1016/j.jacc.2023.05.022
Volume 82, Issue 2, 11 July 2023, Pages 106-108
Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients
Mahesh V. Madhavan, MD, MS,a,b Susheel K. Kodali, MD,a Vinod H. Thourani, MD,c Raj Makkar, MD, d Michael J. Mack, MD,e Samir Kapadia, MD, f John G. Webb, MD,g David J. Cohen, MD, MSC ,b,h Howard C. Herrmann, MD, i Mathew Williams, MD,j Kevin Greason, MD,k Philippe Pibarot, DVM, PHD, l Rebecca T. Hahn, MD, a,b Wael Jaber, MD, f Ke Xu, PH D, m Maria Alu, MS,a,b Craig R. Smith, MD, a Martin B. Leon, MD
doi : 10.1016/j.jacc.2023.04.049
Volume 82, Issue 2, 11 July 2023, Pages 109-123
Previous studies demonstrated transcatheter aortic valve replacement (TAVR) with an earlier generation balloon-expandable valve to be noninferior to surgical aortic valve replacement (SAVR) for death and disabling stroke in intermediate-risk patients with symptomatic, severe aortic stenosis at 5 years. However, limited long-term data are available with the more contemporary SAPIEN 3 (S3) bioprosthesis.
Mid-Term Outcomes of TAVR in Intermediate-Risk Patients: Potential Targets for Improvement∗
Subodh Verma, MD, PHD, a Deepak L. Bhatt, MD, MPH,b Gilbert H.L. Tang, MD, MS C, MBA
doi : 10.1016/j.jacc.2023.04.048
Volume 82, Issue 2, 11 July 2023, Pages 124-127
Impact of Malnutrition in Patients With Heart Failure and Secondary Mitral Regurgitation: The COAPT Trial
Andrea Scotti, MD,a,b, * Augustin Coisne, MD, P HD, a,b,c, * Juan F. Granada, MD,a Elissa Driggin, MD,d Mahesh V. Madhavan, MD, MS, a,d Zhipeng Zhou, MA,a Bj?rn Redfors, MD, P HD, a,d,e Saibal Kar, MD, f,g D. Scott Lim, MD,h David J. Cohen, MD, MS C, a,i JoAnn Lindenfeld, MD,j William T. Abraham, MD,k Michael J. Mack, MD, l Federico M. Asch, MD, m Gregg W. Stone, MD
doi : 10.1016/j.jacc.2023.04.047
Volume 82, Issue 2, 11 July 2023, Pages 128-138
Although malnutrition is associated with poor prognosis in several diseases, its prognostic impact in patients with heart failure (HF) and secondary mitral regurgitation (SMR) is not understood.
Understanding Who Responds to M-TEER in Heart Failure With SMR: Malnutrition Does Not Preclude Benefit∗
Markus S. Anker, MD, a,b,c,d Stephan von Haehling, MD, P HD, e,f Ulf Landmesser, MD
doi : 10.1016/j.jacc.2023.05.014
Volume 82, Issue 2, 11 July 2023, Pages 139-141
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure
Kieran F. Docherty, MBC H B, PH D, a Kirsty McDowell, MBC H B,a Paul Welsh, PHD, a Joanna Osmanska, MBC H B,a Inder Anand, MD, PHD, b Rudolf A. de Boer, MD, PH D, c Lars K?ber, MD, DMSC, d Mikhail N. Kosiborod, MD,e Felipe A. Martinez, MD, f Eileen O’Meara, MD,g Piotr Ponikowski, MD, PH D, h Morten Schou, MD, P HD, i David D. Berg, MD, MPH,j,k Marc S. Sabatine, MD, MPH,j,k David A. Morrow, MD, MPH,j,k Petr Jarolim, MD, PH D, l Ann Hammarstedt, PHD, m Mikaela Sj?strand, MD, PH D, m Anna Maria Langkilde, MD, PHD, m Scott D. Solomon, MD,j Naveed Sattar, MBC HB, PHD, a Pardeep S. Jhund, MBC HB, PHD, a John J.V. McMurray, MD
doi : 10.1016/j.jacc.2023.05.011
Volume 82, Issue 2, 11 July 2023, Pages 142-157
CA125 for Fluid Overload Monitoring: A New Life for an Old Tool∗
Antoni Bayes-Genis, MD, P HD, a,b,c Rafael de la Espriella, MD, PHD, c,d Julio N??ez, MD, PH D
doi : 10.1016/j.jacc.2023.05.016
Volume 82, Issue 2, 11 July 2023, Pages 158-160
Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week
Javier Morales, MD,a Yehuda Handelsman, MD
doi : 10.1016/j.jacc.2023.04.052
Volume 82, Issue 2, 11 July 2023, Pages 161-170
Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the Week
Dinesh K. Kalra, MD, a Mounica Vorla, MD, a Erin D. Michos, MD, MHS,b Anandita Agarwala, MD, c Salim Virani, MD, d P. Bart Duell, MD, e Frederick J. Raal, MMED, P HD
doi : 10.1016/j.jacc.2023.04.050
Volume 82, Issue 2, 11 July 2023, Pages 171-181
The advent of newer and better tolerated antiretroviral therapy has progressively shortened the life expectancy gap between people living with HIV (PWH) and the general population. However, in this aging cohort, cardiovascular disease is now a significant cause of morbidity and mortality despite advances in cardiac care.
